SAN DIEGO, May 20, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCSD), a company developing DNA-based intratumoral cancer immunotherapies, will present data from ongoing clinical and preclinical studies at the New York Academy of Sciences' Emerging Approaches to Cancer Immunotherapy. OncoSec's Chief Scientific Officer Robert H. Pierce, MD, and Chief Medical Officer Mai. H. Le, MD, will present an abstract entitled: "Intratumoral Expression of Plasmid IL-12 Can Increase CD8 TILs and Drive Systemic Anti-Tumor Responses: Rationale for Combination with Anti-PD-1 Blockade" as part of a poster presentation beginning at 12:10 PM ET on Thursday, May 21, 2015 in New York City.
The poster presentation will discuss the unmet medical need of "anti-PD-1 non-responders," which are characterized by the absence of immune cells, and the role of interventions that are specifically focused on increasing tumor-infiltrating lymphocytes (TILs). By increasing TILs and promoting tumor immunogenicity, these interventions may convert anti-PD-1 non-responders to responders. Intratumoral electroporation-mediated gene therapy with DNA-based IL-12 has demonstrated single-agent anti-tumor efficacy in both preclinical tumor models as well as Phase I and II clinical trials in advanced melanoma. The data highlighted in this presentation suggest that intratumoral delivery of DNA-based IL-12 followed by electroporation can increase CD8 TILs, promote tumor immunogenicity, drive systemic anti-tumor responses, and increase the patient population who may benefit from therapeutic PD-1/PD-L1 blockade.
Abstract information is as follows:
- Title: Intratumoral Expression of Plasmid IL-12 Can Increase CD8 TILs and Drive Systemic Anti-Tumor Responses: Rationale for Combination with Anti-PD-1 Blockade
- Presenters: Robert H. Pierce, MD; Mai. H. Le, MD
- Time/Date: 12:10 PM ET, Thursday, May 21, 2015
- Location: The New York Academy of Sciences
About Emerging Approaches to Cancer Immunotherapy
Emerging Approaches to Cancer Immunotherapy is hosted by the New York Academy of Sciences to bring together leading experts in immunotherapy and immunology to discuss emerging approaches, along with the challenges and opportunities faced in this evolving field. Over the past several years, cancer immunotherapy has made progress both conceptually and in clinical practice. Led by landmark studies in the setting of metastatic melanoma, many of the findings of this field are being generalized both to hematological malignancies and to other solid tumors. Areas of investigation such as checkpoint blockade inhibitors, advanced tumor vaccination studies, and adoptive T-cell therapies are changing the face of cancer treatment, and will be discussed at the upcoming meeting. For more information, please visit: www.nyas.org.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse™ for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse™ in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
OncoSec Medical Inc. Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
OncoSec Medical Inc.
OncoSec Medical Inc.
SOURCE OncoSec Medical Inc.